Literature DB >> 1849547

[125I]Iodomelatonin-binding sites in the pigeon brain: binding characteristics, regional distribution and diurnal variation.

H Yuan1, S F Pang.   

Abstract

The binding and pharmacological characteristics of melatonin-binding sites labelled by [125I]iodomelatonin in membrane preparations from the pigeon brain were determined. Specific binding of [125I]iodomelatonin in the membrane preparations of pigeon brain was rapid, stable, saturable and reversible. The [125I]iodomelatonin-binding sites had the following order of pharmacological affinities: melatonin greater than 6-chloromelatonin greater than N-acetylserotonin much greater than 5-hydroxytryptamine greater than tryptamine greater than 5-methoxytryptophol, greater than 1-acetylindole-3-carboxytryptamine, 5-hydroxyindole-3-acetic acid, L-tryptophan and 3-acetylindole. Compounds known to act on serotonin receptors, adrenoceptors or cholinoceptors were inactive compared with melatonin. Of the various brain regions studied, melatonin binding was greatest in the hypothalamus, intermediate in the mid-brain, pons-medulla and telencephalon, and low in the cerebellum. Subcellular fraction studies indicated that 39% of the binding was located in the mitochondrial fraction, 34% in the nuclear fraction, 21% in the microsomal fraction and 5.6% in the cytosol fraction. Scatchard analysis of the membrane preparations revealed a dissociation constant (Kd) of 206.3 +/- 57.9 pmol/l and a total number of binding sites (Bmax) of 26.7 +/- 1.9 fmol/mg protein in the middle of the light period (mid-light). In addition, saturation studies demonstrated that [125I]iodomelatonin-binding sites in pigeon brain membrane preparations were 36.2% higher at mid-light (26.7 +/- 1.9 fmol/mg protein) than in the middle of the dark period (19.6 +/- 1.25 fmol/mg protein), with no significant variation in their binding affinities.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849547     DOI: 10.1677/joe.0.1280475

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  8 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

Review 2.  Melatonin and the electron transport chain.

Authors:  Rüdiger Hardeland
Journal:  Cell Mol Life Sci       Date:  2017-08-07       Impact factor: 9.261

Review 3.  Role of melatonin in neurodegenerative diseases.

Authors:  V Srinivasan; S R Pandi-Perumal; G Jm Maestroni; A I Esquifino; R Hardeland; D P Cardinali
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

4.  A novel endogenous indole protects rodent mitochondria and extends rotifer lifespan.

Authors:  Burkhard Poeggeler; Kumar Sambamurti; Sandra L Siedlak; George Perry; Mark A Smith; Miguel A Pappolla
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

5.  Effect of pinealectomy and the light/dark cycle on 2-[125I]iodomelatonin binding in the chick optic tectum.

Authors:  J A Siuciak; M L Dubocovich
Journal:  Cell Mol Neurobiol       Date:  1993-06       Impact factor: 5.046

6.  Melatonin in Alzheimer's disease and other neurodegenerative disorders.

Authors:  V Srinivasan; S R Pandi-Perumal; D P Cardinali; B Poeggeler; R Hardeland
Journal:  Behav Brain Funct       Date:  2006-05-04       Impact factor: 3.759

Review 7.  Melatonin in Alzheimer's disease.

Authors:  Li Lin; Qiong-Xia Huang; Shu-Sheng Yang; Jiang Chu; Jian-Zhi Wang; Qing Tian
Journal:  Int J Mol Sci       Date:  2013-07-12       Impact factor: 5.923

8.  Neuroendocrine regulation of gonadotropin secretion in seasonally breeding birds.

Authors:  Takayoshi Ubuka; George E Bentley; Kazuyoshi Tsutsui
Journal:  Front Neurosci       Date:  2013-03-25       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.